Participants and baseline results
polycystic ovary syndrome, PCOS, anovulation, oligo-ovulation
POLYCYSTIC OVARIES, ANOVULATION, POLYCYSTIC OVARY SYNDROME, HYPERANDROGENISM, INSULIN RESISTANCE
Of the 64 overweight/obese women with PCOS starting on treatment,60 patients completed the study (Flow chart of the study design.Baseline characteristics of Intent-to-treat participants.Values are presented as Mean±SD, median(interquartile range) and percentages (frequencies); COMB, combination of metformin and beinaglutide; MET, metformin; BMI, body mass index; WC, waist circumference; WHR, waist-to-hip ratio; WHtR, waist to height ratio; TT, total testosterone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; mFG, modified Ferriman–Gallwey score; AFC, antral follicle count; FPG, fasting plasma glucose, OGTT 2hPG, 2-hours plasma glucose after OGTT; FINS, fasting insulin; OGTT 2hINS, 2 hours serum insulin after OGTT; HOMA-IR, homeostasis model assessment–insulin resistance; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol;LDL-C, low-density lipoprotein cholesterol; TG, triglyceride. HA, Hyperandrogenism; OA, oligo-ovulation or anovulation; PCO, polycystic ovaries.Before and after 12-week treatment parameters of the participants with polycystic ovary syndrome in each group.Values are presented as Mean±SD and median(interquartile range). COMB, combination of metformin and beinaglutide; MET, metformin; BMI, body mass index; WC, waist circumference; WHR, waist-to-hip ratio; WHtR, waist to height ratio; TT, total testosterone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; mFG, modified Ferriman–Gallwey score; AFC, antral follicle count; FPG, fasting plasma glucose, OGTT 2hPG, 2-hours plasma glucose after OGTT; FINS, fasting insulin; OGTT 2hINS, 2 hours serum insulin after OGTT; HOMA-IR, homeostasis model assessment–insulin resistance; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride. Bolded P values indicate less than 0.05,statistically significant.Changes of parameters of the participants with polycystic ovary syndrome in each group.Values are presented as Mean ± SD and median(interquartile range). COMB, combination of metformin and beinaglutide; MET, metformin; BMI, body mass index;WC, waist circumference; WHR, waist-to-hip ratio; WHtR, waist to height ratio;TT, total testosterone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; mFG, modified Ferriman–Gallwey score; AFC, antral follicle count; FPG, fasting plasma glucose, OGTT 2hPG, 2-hours plasma glucose after OGTT; FINS, fasting insulin; OGTT 2hINS, 2 hours serum insulin after OGTT; HOMA-IR, homeostasis model assessment–insulin resistance; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride. Bolded P values indicate less than 0.05,statistically significant.